FeRx targets MCT (Magnetic Targeted Carrier) method at GI (gastrointestinal) diseases:
This article was originally published in Clinica
Executive Summary
Preclinical results have suggested that FeRx' magnetic field-based drug delivery technique is a feasible method for delivering compounds to the gastrointestinal (GI) tract, the San Diego, California firm has reported. The Magnetic Targeted Carrier (MTC) technique may help treat GI diseases, such as inflammatory bowl disease and cancerous tumours of the oesophagus, stomach and colon, via an intra-luminal route of administration. FeRx has previously demonstrated delivery of MTCs via intra-arterial and intra-vesical routes of administration, possibly leading to the treatment of a variety of solid tumours, including those of the liver and bladder (see Clinica No 1004, p 24).